Managing the toxicities of CAR T‐cell therapy von Neelapu, Sattva S.

Volltext

CAR-T efficacy: is conditioning the key? von Neelapu, Sattva S.

Volltext

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy von Morris, Emma C., Neelapu, Sattva S., Giavridis, Theodoros, Sadelain, Michel

Volltext

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study von Crump, Michael, Neelapu, Sattva S., Farooq, Umar, Van Den Neste, Eric, Kuruvilla, John, Westin, Jason, Link, Brian K., Hay, Annette, Cerhan, James R., Zhu, Liting, Boussetta, Sami, Feng, Lei, Maurer, Matthew J., Navale, Lynn, Wiezorek, Jeff, Go, William Y., Gisselbrecht, Christian

Volltext

CAR-T failure: beyond antigen loss and T cells von Strati, Paolo, Neelapu, Sattva S.

Volltext

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial von Locke, Frederick L, Ghobadi, Armin, Jacobson, Caron A, Miklos, David B, Lekakis, Lazaros J, Oluwole, Olalekan O, Lin, Yi, Braunschweig, Ira, Hill, Brian T, Timmerman, John M, Deol, Abhinav, Reagan, Patrick M, Stiff, Patrick, Flinn, Ian W, Farooq, Umar, Goy, Andre, McSweeney, Peter A, Munoz, Javier, Siddiqi, Tanya, Chavez, Julio C, Herrera, Alex F, Bartlett, Nancy L, Wiezorek, Jeffrey S, Navale, Lynn, Xue, Allen, Jiang, Yizhou, Bot, Adrian, Rossi, John M, Kim, Jenny J, Go, William Y, Neelapu, Sattva S

Volltext

CAR Treg cells: prime suspects in therapeutic resistance von Saini, Neeraj, Neelapu, Sattva S.

Volltext

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial von Jacobson, Caron A, Chavez, Julio C, Sehgal, Alison R, William, Basem M, Munoz, Javier, Salles, Gilles, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Yakoub-Agha, Ibrahim, Oluwole, Olalekan O, Fung, Henry Chi Hang, Rosenblatt, Joseph, Rossi, John M, Goyal, Lovely, Plaks, Vicki, Yang, Yin, Vezan, Remus, Avanzi, Mauro P, Neelapu, Sattva S

Volltext

A CAR against CAR for unintended consequences von Neelapu, Sattva S.

Volltext

Cancer immunotherapy: Strategies for personalization and combinatorial approaches von Sathyanarayanan, Vishwanath, Neelapu, Sattva S.

Volltext

The promise of CAR T-cell therapy in aggressive B-cell lymphoma von Nair, Ranjit, Neelapu, Sattva S.

Volltext

How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies von Reagan, Patrick M., Neelapu, Sattva S.

Volltext

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities von Neelapu, Sattva S., Tummala, Sudhakar, Kebriaei, Partow, Wierda, William, Gutierrez, Cristina, Locke, Frederick L., Komanduri, Krishna V., Lin, Yi, Jain, Nitin, Daver, Naval, Westin, Jason, Gulbis, Alison M., Loghin, Monica E., de Groot, John F., Adkins, Sherry, Davis, Suzanne E., Rezvani, Katayoun, Hwu, Patrick, Shpall, Elizabeth J.

Volltext

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium von Nastoupil, Loretta J., Jain, Michael D., Feng, Lei, Spiegel, Jay Y., Ghobadi, Armin, Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick, Oluwole, Olalekan, McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison R., Goy, Andre, Hill, Brian T., Vu, Khoan, Andreadis, Charalambos, Munoz, Javier, Westin, Jason, Chavez, Julio C., Cashen, Amanda, Bennani, N. Nora, Rapoport, Aaron P., Vose, Julie M., Miklos, David B., Neelapu, Sattva S., Locke, Frederick L.

Volltext

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study von Takahashi, Koichi, MD, Wang, Feng, PhD, Kantarjian, Hagop, Prof, Doss, Denaha, MS, Khanna, Kanhav, MS, Thompson, Erika, MS, Zhao, Li, PhD, Patel, Keyur, MD, Neelapu, Sattva, MD, Gumbs, Curtis, BS, Bueso-Ramos, Carlos, Prof, DiNardo, Courtney D, MD, Colla, Simona, PhD, Ravandi, Farhad, Prof, Zhang, Jianhua, PhD, Huang, Xuelin, PhD, Wu, Xifeng, Prof, Samaniego, Felipe, MD, Garcia-Manero, Guillermo, Prof, Futreal, P Andrew, Prof

Volltext

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma von Strati, Paolo, Varma, Ankur, Adkins, Sherry, Nastoupil, Loretta J., Westin, Jason R., Hagemeister, Fredrick B., Fowler, Nathan H., Lee, Hun J., Fayad, Luis E., Samaniego, Felipe, Ahmed, Sairah, Chen, Yiming, Horowitz, Sandra, Arafat, Sara, Johncy, Swapna, Kebriaei, Partow, Mulanovich, Victor Eduardo, Heredia, Ella Ariza, Neelapu, Sattva S.

Volltext

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial von Westin, Jason R, MD, Chu, Fuliang, PhD, Zhang, Min, PhD, Fayad, Luis E, MD, Kwak, Larry W, Prof, Fowler, Nathan, MD, Romaguera, Jorge, Prof, Hagemeister, Fredrick, Prof, Fanale, Michelle, MD, Samaniego, Felipe, MD, Feng, Lei, MS, Baladandayuthapani, Veerabhadran, PhD, Wang, Zhiqiang, PhD, Ma, Wencai, PhD, Gao, Yanli, MS, Wallace, Michael, Prof, Vence, Luis M, PhD, Radvanyi, Laszlo, Prof, Muzzafar, Tariq, MD, Rotem-Yehudar, Rinat, PhD, Davis, R Eric, MD, Neelapu, Sattva S, Dr

Volltext

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors von Liu, Enli, Marin, David, Banerjee, Pinaki, Macapinlac, Homer A, Thompson, Philip, Basar, Rafet, Nassif Kerbauy, Lucila, Overman, Bethany, Thall, Peter, Kaplan, Mecit, Nandivada, Vandana, Kaur, Indresh, Nunez Cortes, Ana, Cao, Kai, Daher, May, Hosing, Chitra, Cohen, Evan N, Kebriaei, Partow, Mehta, Rohtesh, Neelapu, Sattva, Nieto, Yago, Wang, Michael, Wierda, William, Keating, Michael, Champlin, Richard, Shpall, Elizabeth J, Rezvani, Katayoun

Volltext

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial von Neelapu, Sattva S., Dickinson, Michael, Munoz, Javier, Ulrickson, Matthew L., Thieblemont, Catherine, Oluwole, Olalekan O., Herrera, Alex F., Ujjani, Chaitra S., Lin, Yi, Riedell, Peter A., Kekre, Natasha, de Vos, Sven, Lui, Christine, Milletti, Francesca, Dong, Jinghui, Xu, Hairong, Chavez, Julio C.

Volltext

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma von Locke, Frederick L., Rossi, John M., Neelapu, Sattva S., Jacobson, Caron A., Miklos, David B., Ghobadi, Armin, Oluwole, Olalekan O., Reagan, Patrick M., Lekakis, Lazaros J., Lin, Yi, Sherman, Marika, Better, Marc, Go, William Y., Wiezorek, Jeffrey S., Xue, Allen, Bot, Adrian

Volltext